Abstract
Background
Visible light (400 to 700 nm) is common in our environment, comprising 44% of total solar radiation and a large component of environmental light exposure. The effects of visible light on skin remain undefined. The red light portion of the visible spectrum (600 to 700 nm) may be used to treat skin diseases as a monotherapeutic modality or in combination with other agents. Light-emitting diode-red light (LED-RL) phototherapy may represent an important advance in light-based treatment modalities because it is non-invasive, inexpensive, portable, and easily combinable with other therapies. We previously determined the maximum tolerated dose (MTD) of high-fluence LED-RL (HF-LED-RL) in skin of color individuals to be 320 J/cm2. To the best of our knowledge, no clinical trials have been performed to determine the safety of higher doses of HF-LED-RL in Caucasian non-Hispanic individuals. The aim of this study is to investigate the safety of HF-LED-RL at doses of 480 and 640 J/cm2 in healthy Caucasian non-Hispanic individuals.
Methods
This is a single-blind, dose-escalation, randomized, controlled, phase I trial titled Safety Trial Assessing Red-light on Skin (STARS) 2. Healthy subjects will be randomly assigned to groups of five (three subjects randomly assigned to HF-LED-RL phototherapy and two subjects randomly assigned to mock therapy). Subjects in group 1 will receive HF-LED-RL or mock irradiation at the starting dose of 480 J/cm2, and the dose will be escalated in the subsequent group (group 2) to 640 J/cm2. The MTD is defined as the dose level below the dose at which two or more subjects (>20% of the cohort) experience a dose-limiting toxicity (DLT). After either the MTD is established or the study endpoint of 640 J/cm2 is achieved, additional HF-LED-RL phototherapy subjects and mock therapy subjects will be enrolled at that fluence (group 3) for a total number of up to 60 subjects. Each subject will receive a total of nine irradiation sessions, three times per week for three consecutive weeks.
Discussion
This follow-up study aims to provide important knowledge about safety and cutaneous effects of HF-LED-RL phototherapy of 480 and 640 J/cm2 in Caucasian non-Hispanic subjects. The importance of this clinical trial is that it may establish new treatment paradigms and a safety profile for LED-RL based on race and ethnicity.
Trial registration
ClinicalTrials.gov Identifier: NCT03433222. Registered on February 1, 2018 - Retrospectively registered.
Protocol date and version: January 12, 2018; version 1.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Stanford University, Department of Dermatology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
2 Sacramento VA Medical Center, Dermatology Service, Mather, USA (GRID:grid.430980.6) (ISNI:0000 0004 0395 4002); University of California Davis, Department of Dermatology, Sacramento, USA (GRID:grid.27860.3b) (ISNI:0000 0004 1936 9684)
3 The State University of New York Downstate Medical Center, Department of Dermatology, Brooklyn, USA (GRID:grid.262863.b) (ISNI:0000 0001 0693 2202)
4 University of California Davis, Department of Dermatology, Sacramento, USA (GRID:grid.27860.3b) (ISNI:0000 0004 1936 9684)
5 The State University of New York, University of Buffalo, School of Nursing, Buffalo, USA (GRID:grid.273335.3) (ISNI:0000 0004 1936 9887)
6 The State University of New York Downstate Medical Center, Department of Dermatology, Brooklyn, USA (GRID:grid.262863.b) (ISNI:0000 0001 0693 2202); Dermatology Service, VA New York Harbor Healthcare System – Brooklyn Campus, Brooklyn, USA (GRID:grid.262863.b)